OncoMatch/Clinical Trials/NCT04673942
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
Is NCT04673942 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including AdAPT-001 and Checkpoint Inhibitor, Immune for solid tumor, adult.
Treatment: AdAPT-001 · Checkpoint Inhibitor, Immune — AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: all conventional therapies considered appropriate by Investigator
who have received all conventional therapies considered appropriate by Investigator
Cannot have received: adenoviral therapy
Exception: except vaccination against infectious disease
Prior adenoviral therapy for any indication except vaccination against infectious disease
Cannot have received: chemotherapy
Exception: within 14 days of study treatment
Chemotherapy or immunotherapy within 14 days of study treatment
Cannot have received: immunotherapy
Exception: within 14 days of study treatment
Chemotherapy or immunotherapy within 14 days of study treatment
Lab requirements
Blood counts
Absolute neutrophil count > 1,500 cells/mm3; Platelet count > 75,000/mm3; Hemoglobin (HGB) ≥ 8.0 g/dL
Kidney function
Serum Creatinine < 1.5 x ULN
Liver function
Bilirubin < 1.5 x ULN; AST (SGOT) and ALT (SGPT) < 3.0 x ULN; Alkaline Phosphatase < 2.5 x ULN
Subject has acceptable liver function at Screening...Subject has a Serum Creatinine < 1.5 x ULN...Subject has acceptable hematologic status at Screening...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- California Cancer Associates for Research and Excellence, cCARE · San Marcos, California
- Providence Saint John's Health Center · Santa Monica, California
- Cleveland Clinic · Cleveland, Ohio
- Mary Crowley Cancer Research · Dallas, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04673942 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior adenoviral therapy, chemotherapy, immunotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages